Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 17Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Thyroid Neoplasms 7Pancreatic Neoplasms 7Cholangiocarcinoma 7Breast Neoplasms 7Esophageal Neoplasms 6Sarcoma 5Neuroendocrine Tumors 5Lung Neoplasms 5Head and Neck Neoplasms 5Gastrointestinal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma 5Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neoplasms by Site 4Lung Diseases 4Liver Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Gastro-enteropancreatic neuroendocrine tumor × Gastrointestinal × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡